Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
In summary: It did not work in those patients with stages II-III.
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial
Author(s): Ruo-Xi Hong, MD1; Fei Xu, MD1; Wen Xia, MD1; Yue-E Teng, MD2; Qu-Chang Ouyang, MD3; Qiu-Fan Zheng, MD1; Zhong-Yu Yuan, MD1; Dong-Shao Chen, MD1; Kui-Kui Jiang, MD1; Ying Lin, MD4; Zhen Dai, MSc5; Xin-Lan Liu, MD6; Qian-Jun Chen, MD7; Xin-Hong Wu, MD8; Yan-Xia Shi, MD1; Jia-Jia Huang, MD1; Xin An, MD1; Cong Xue, MD1; Xi-Wen Bi, MD1; Mei-Ting Chen, MD1; Hui Li, MD9; He-Rui Yao, MD10; Guo-Rong Zou, MD11; Heng Huang, MD12; Jing-Min Zhang, MD1; Shu-Sen Wang, MD1
Source: https://doi.org/10.1200/JCO.24.00938
Dr. Maen Hussein's Thoughts
Metronomic dose: low dose cytotoxic therapy at high frequency was studied in combination with an AI (cape at 500mg TID) and showed superiority over AI single agent, this may be an option for patients not tolerating CKD4/6 inhibitors.
PURPOSE
The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.
METHODS
Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety.
RESULTS
A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment.
CONCLUSION
The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.
Author Affiliations
1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China;2Department of Breast Internal Medicine, The First Hospital of China Medical University, Shenyang, China;3Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China;4Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;5Chengdu Center for Disease Control and Prevention, Chengdu, China;6Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China;7Department of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China;8Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China;9Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China;10Breast Tumor Centre, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;11Department of Oncology, Panyu District Cancer Institute, Panyu Central Hospital, Guangzhou, China;12Department of Breast Surgery, Lianjiang People’s Hospital, Lianjiang, ChinaRelated Articles
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
